Nanosyn Sells to Element Materials Technology
BroadOak Partners advises Nanosyn on the sale of the company to Element Materials Technology (“Element”). Nanoysn is a full-service drug discovery CDMO that provides chemistry, biology, API, and formulation services to pharmaceutical companies. The full press release is below. Element further bolsters its pharmaceuticals offering with Nanosyn acquisition London, UK – October 11, 2021 – […]
BroadOak Leads Acquisition of Particle Dynamics
An investor group led by BroadOak Capital Partners acquired Particle Dynamics from Edgewater Capital Partners. Particle Dynamics is a global leader in particle processing, delivery technologies, and finished dose manufacturing for the pharmaceutical, over-the-counter, and nutraceutical markets. The full press release is below. Particle Dynamics Announces Sale to New Ownership Group Led by BroadOak Capital […]
PBS Biotech Raises $10M in Growth Capital
Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the company to expand and industrialize its portfolio of single-use bioreactor systems and contract process development services. The full press release is below. PBS Biotech Raises $10M to Provide Scale-Up Manufacturing Solutions for Cell Therapies […]
Vigene Biosciences Acquired by Charles River Laboratories
BroadOak portfolio company Vigene Biosciences was acquired by Charles River Laboratories. Vigene Biosciences is a leading CDMO providing viral vector manufacturing services for the cell and gene therapy market. The full press release is below. Charles River Laboratories Completes Acquisition of Vigene Biosciences WILMINGTON, Mass.–(BUSINESS WIRE)–Jun. 29, 2021– Charles River Laboratories International, Inc. (NYSE: CRL) […]